Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism

 
• By Joseph Haas
  
Bristol-Myers-Squib_685347493_1200.jpg
Bristol sees positive early trends for the Opdivo/Yervoy combo in first-line lung cancer

More from Earnings

More from Business